Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

A bill introduced this legislative session aims to prohibit the sale of certain marijuana products to customers aged 21 to 25 ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Learn more about whether Glaukos Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

Therapists who work in long-term care know a lot about time management and productivity. We know that our billable time must closely match our time on the ...

Q4 2024 Management View CEO Kevin Hykes highlighted strong revenue growth of $15.3 million for Q4 2024, representing a 36% increase year-over-year. U.S. Heart Failure revenues grew by 41%, supported ...